172 related articles for article (PubMed ID: 31443574)
1. Untargeted Metabolomic Profile for the Detection of Prostate Carcinoma-Preliminary Results from PARAFAC2 and PLS-DA Models.
Amante E; Salomone A; Alladio E; Vincenti M; Porpiglia F; Bro R
Molecules; 2019 Aug; 24(17):. PubMed ID: 31443574
[TBL] [Abstract][Full Text] [Related]
2. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
5. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis.
Chong J; Wishart DS; Xia J
Curr Protoc Bioinformatics; 2019 Dec; 68(1):e86. PubMed ID: 31756036
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.
Amante E; Cerrato A; Alladio E; Capriotti AL; Cavaliere C; Marini F; Montone CM; Piovesana S; Laganà A; Vincenti M
Sci Rep; 2022 Mar; 12(1):4361. PubMed ID: 35288652
[TBL] [Abstract][Full Text] [Related]
7. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
8. Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling.
Fiehn O
Curr Protoc Mol Biol; 2016 Apr; 114():30.4.1-30.4.32. PubMed ID: 27038389
[TBL] [Abstract][Full Text] [Related]
9. New findings on urinary prostate cancer metabolome through combined GC-MS and
Lima AR; Pinto J; Barros-Silva D; Jerónimo C; Henrique R; Bastos ML; Carvalho M; Guedes Pinho P
Metabolomics; 2020 Jun; 16(6):70. PubMed ID: 32495062
[TBL] [Abstract][Full Text] [Related]
10. Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS.
Lima AR; Araújo AM; Pinto J; Jerónimo C; Henrique R; Bastos ML; Carvalho M; Guedes de Pinho P
Sci Rep; 2018 Apr; 8(1):5539. PubMed ID: 29615722
[TBL] [Abstract][Full Text] [Related]
11. Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.
Corona G; Cannizzaro R; Miolo G; Caggiari L; De Zorzi M; Repetto O; Steffan A; De Re V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518896
[TBL] [Abstract][Full Text] [Related]
12. Identification of Putative Biomarkers Specific to Foodborne Pathogens Using Metabolomics.
Jadhav SR; Shah RM; Karpe AV; Beale DJ; Kouremenos KA; Palombo EA
Methods Mol Biol; 2019; 1918():149-164. PubMed ID: 30580406
[TBL] [Abstract][Full Text] [Related]
13. Using deep learning to evaluate peaks in chromatographic data.
Risum AB; Bro R
Talanta; 2019 Nov; 204():255-260. PubMed ID: 31357290
[TBL] [Abstract][Full Text] [Related]
14. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
Wu H; Liu T; Ma C; Xue R; Deng C; Zeng H; Shen X
Anal Bioanal Chem; 2011 Aug; 401(2):635-46. PubMed ID: 21626193
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
17. Global and untargeted metabolomics evidence of the protective effect of different extracts of Dipsacus asper Wall. ex C.B. Clarke on estrogen deficiency after ovariectomia in rats.
Tao Y; Chen X; Li W; Cai B; Di L; Shi L; Hu L
J Ethnopharmacol; 2017 Mar; 199():20-29. PubMed ID: 28132861
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
